Drug pricing evolution in hepatitis c

PLoS ONE

Volumn 11, Issue 6, 2016, Pages

  Vernaz, Nathalie ^a   Girardin, François ^a   Goossens, Nicolas ^a   Brügger, Urs ^b   Riguzzi, Marco ^b   Perrier, Arnaud ^a   Negro, Francesco ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b ZURICH UNIVERSITY OF APPLIED SCIENCES   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; BOCEPREVIR; DASABUVIR; LEDIPASVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; PEGINTERFERON ALPHA; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN; SIMEPREVIR; SOFOSBUVIR; TELAPREVIR; ANTIVIRUS AGENT; INTERFERON; OLIGOPEPTIDE; RITONAVIR;

ARTICLE; COST BENEFIT ANALYSIS; DRUG COST; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 1; LINEAR REGRESSION ANALYSIS; MONOTHERAPY; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); SENSITIVITY ANALYSIS; SUSTAINED VIRAL RESPONSE; SWITZERLAND; TREATMENT DURATION; VIRAL PHENOMENA AND FUNCTIONS; COMBINATION DRUG THERAPY; DRUG DEVELOPMENT; DRUG EFFECTS; ECONOMICS; GENOTYPE; HEPACIVIRUS; HUMAN; UNITED STATES; VIROLOGY;

ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; DRUG DISCOVERY; DRUG THERAPY, COMBINATION; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HUMANS; INTERFERONS; OLIGOPEPTIDES; RIBAVIRIN; RITONAVIR; SOFOSBUVIR; SWITZERLAND; UNITED STATES;

EID: 84976345206     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0157098     Document Type: Article

References (44)

1. Pfeil AM, Reich O, Guerra IM, Cure S, Negro F, Mullhaupt B, et al. Cost-effectiveness analysis of sofosbuvir compared to current standard treatment in swiss patients with chronic hepatitis C. PloS one. 2015; 10(5):e0126984. doi: 10.1371/journal.pone.0126984 PMID: 25974722
2. Manns MP, Foster GR, Rockstroh JK, Zeuzem S, Zoulim F, Houghton M. The way forward in HCV treatment-finding the right path. Nat Rev Drug Discov. 2007; 6(12):991-1000. PMID: 18049473
3. Marinho RT, Barreira DP. Hepatitis C, stigma and cure. World J Gastroenterol. 2013; 19(40):6703-9. doi: 10.3748/wjg.v19.i40.6703 PMID: 24187444
4. Lindsay KL, Trepo C, Heintges T, Shiffman ML, Gordon SC, Hoefs JC, et al. A randomized, doubleblind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C. Hepatology. 2001; 34(2):395-403. PMID: 11481625
5. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet. 2001; 358(9286):958-65. PMID: 11583749
6. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, Bzowej NH, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 2011; 364(25):2405-16. doi: 10.1056/NEJMoa1012912 PMID: 21696307
7. Poordad F, McCone J, Bacon BR, Bruno S, Manns MP, Sulkowski MS, et al. Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13):1195-206. doi: 10.1056/ NEJMoa1010494 PMID: 21449783
8. Silva MO, Treitel M, Graham DJ, Curry S, Frontera MJ, McMonagle P, et al. Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3. J Hepatol. 2013; 59 (1):31-7. doi: 10.1016/j.jhep.2013.02.018 PMID: 23454058
9. Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014; 370(21):1983-92. doi: 10.1056/ NEJMoa1402338 PMID: 24795200
10. Kowdley KV, Gordon SC, Reddy KR, Rossaro L, Bernstein DE, Lawitz E, et al. Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis. N Engl J Med. 2014; 370(20):1879-88. doi: 10. 1056/NEJMoa1402355 PMID: 24720702
11. Lawitz E, Mangia A, Wyles D, Rodriguez-Torres M, Hassanein T, Gordon SC, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013; 368(20):1878-87. doi: 10.1056/ NEJMoa1214853 PMID: 23607594
12. Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, et al. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014; 370(17):1594-603. doi: 10.1056/ NEJMoa1315722 PMID: 24720703
13. Jacobson IM, Dore GJ, Foster GR, Fried MW, Radu M, Rafalsky VV, et al. Simeprevir with pegylated interferon alfa 2a plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-1): a phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2014; 384 (9941):403-13. doi: 10.1016/S0140-6736(14)60494-3 PMID: 24907225
14. Manns M, Marcellin P, Poordad F, de Araujo ES, Buti M, Horsmans Y, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014; 384 (9941):414-26. doi: 10.1016/S0140-6736(14)60538-9 PMID: 24907224
15. Sulkowski MS, Gardiner DF, Rodriguez-Torres M, Reddy KR, Hassanein T, Jacobson I, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014; 370 (3):211-21. doi: 10.1056/NEJMoa1306218 PMID: 24428467
16. Kamal-Yanni M. Hepatitis C drug affordability. Lancet Glob Health. 2015; 3(2):e73-4. doi: 10.1016/ S2214-109X(14)70365-1 PMID: 25617196
17. Kmietowicz Z. Thousands of patients in England to get new hepatitis C drugs. BMJ. 2015; 350:h3222. doi: 10.1136/bmj.h3222 PMID: 26071408
18. Andrieux-Meyer I CJ, Aff onso de Araújo E, Hamid S. Disparity in market prices for hepatitis C virus direct-acting drugs. Lancet Glob Health. 2015; 3:676-7.
19. DiMasi JA, Hansen RW, Grabowski HG. The price of innovation: new estimates of drug development costs. J Health Econ. 2003; 22(2):151-85. PMID: 12606142
20. Mailankody S, Prasad V. Five Years of Cancer Drug Approvals: Innovation, Efficacy, and Costs. JAMA Oncol. 2015; 1(4):539-40. doi: 10.1001/jamaoncol.2015.0373 PMID: 26181265
21. Munos B. Lessons from 60 years of pharmaceutical innovation. Nat Rev Drug Discov. 2009; 8(12):959-68. doi: 10.1038/nrd2961 PMID: 19949401
22. Paris V, Docteur E. Pharmaceutical pricing and reimbursement policies in Switzerland. OCDE. 2007; 27.
23. Mullhaupt B, Bruggmann P, Bihl F, Blach S, Lavanchy D, Razavi H, et al. Modeling the Health and Economic Burden of Hepatitis C Virus in Switzerland. PloS one. 2015; 10(6):e0125214. doi: 10.1371/ journal.pone.0125214 PMID: 26107467
24. Twenty-Five Years of Progress against Hepatitis C: setbacks and Stepping Stones. PRMA. December 2014.
25. Girardin FG, N., Vernaz N., Negro F. Rethinking the reimbursement policy of direct acting antivirals against chronic hepatitis C. Rev Med Suisse. September 2 2015; 484:1610-5.
26. Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, et al. Sustained virological response: a milestone in the treatment of chronic hepatitis C. World J Gastroenterol. 2013; 19 (18):2793-8. doi: 10.3748/wjg.v19.i18.2793 PMID: 23687416
27. Müller KR. Ispor Global Health Care Systems Road Map: Switzerland. International Society for Pharmacoeconomics and Outcomes Research. April 2011.
28. Afdhal N, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014; 370(20):1889-98. doi: 10.1056/NEJMoa1402454 PMID: 24725239
29. Vernaz N, Haller G, Girardin F, Huttner B, Combescure C, Dayer P, et al. Patented drug extension strategies on healthcare spending: a cost-evaluation analysis. PLoS Med. 2013; 10(6):e1001460. doi: 10. 1371/journal.pmed.1001460 PMID: 23750120
30. Neumann PJ, Chambers JD, Simon F, Meckley LM. Risk-sharing arrangements that link payment for drugs to health outcomes are proving hard to implement. Health Aff (Millwood). 2011; 30(12):2329-37.
31. McCarthy M. US Senate committee launches investigation into drug pricing. BMJ. 2015; 351:h5989. doi: 10.1136/bmj.h5989 PMID: 26553078
32. van de Ven N, Fortunak J, Simmons B, Ford N, Cooke GS, Khoo S, et al. Minimum target prices for production of direct-acting antivirals and associated diagnostics to combat hepatitis C virus. Hepatology. 2015; 61(4):1174-82. doi: 10.1002/hep.27641 PMID: 25482139
33. Bichoupan K, Martel-Laferriere V, Sachs D, Ng M, Schonfeld EA, Pappas A, et al. Costs of telaprevirbased triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology. 2014; 60 (4):1187-95. doi: 10.1002/hep.27340 PMID: 25065814
34. Messori A, Maratea D, Fadda V, Trippoli S. Letter: estimating the cost-neutral price of sofosbuvir-based triple therapy for the treatment of naive patients with genotype 1 HCV infection in Italy. Aliment Pharmacol Ther. 2014; 40(2):217-8. doi: 10.1111/apt.12823 PMID: 24946068
35. Chhatwal J, Kanwal F, Roberts MS, Dunn MA. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med. 2015; 162(6):397-406. doi: 10.7326/M14-1336 PMID: 25775312
36. Najafzadeh M, Andersson K, Shrank WH, Krumme AA, Matlin OS, Brennan T, et al. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus. Ann Intern Med. 2015; 162(6):407-19. doi: 10. 7326/M14-1152 PMID: 25775313
37. van de Vooren K, Curto A, Garattini L. Pricing of forthcoming therapies for hepatitis C in Europe: beyond cost-effectiveness? Eur J Health Econ. 2015; 16(4):341-5. doi: 10.1007/s10198-014-0653-x PMID: 25407841
38. Zoulim F, Liang TJ, Gerbes AL, Aghemo A, Deuffic-Burban S, Dusheiko G, et al. Hepatitis C virus treatment in the real world: optimising treatment and access to therapies. Gut. 2015; 64(11):1824-33. doi: 10.1136/gutjnl-2015-310421 PMID: 26449729
39. Bach PB. New Math on Drug Cost-Effectiveness. N Engl J Med. 2015; 373(19):1797-9. doi: 10.1056/ NEJMp1512750 PMID: 26535510
40. McCarthy M. New drug for hepatitis C contributes to 13% rise in spending on prescription drugs in US. BMJ. 2015; 350:h2055. doi: 10.1136/bmj.h2055 PMID: 25888306
41. van de Vooren K, Duranti S, Curto A, Garattini L. A critical systematic review of budget impact analyses on drugs in the EU countries. Appl Health Econ Health Policy. 2014; 12(1):33-40. doi: 10.1007/ s40258-013-0064-7 PMID: 24158922
42. Brunetto MR, De Luca A, Messori A, Zignego AL. Reducing the price of new hepatitis C drugs in the Tuscany region of Italy. BMJ. 2015; 350:h3363. doi: 10.1136/bmj.h3363 PMID: 26108546
43. Novartis to test new pricing model with heart failure drug. Reuters. 30 June 2015. [cited: April 24 2016]. Available: http://reuters.com/article/us-novartis-heart-idUSKCN0PA1N720150630.
44. Ezekiel J. Emanuel: The Solution to Drug Prices. New York Times. 9 September 2015 [cited: April 24 2016]. Available: http://nytimes.com/2015/09/09/opinion/the-solution-to-drug-prices.html.